春节前夕,医药圈上演了一场重磅大戏——信达生物和礼来这对“老搭档”,达成了第七次全球战略合作,将携手推进肿瘤及免疫领域创新药物的全球研发。根据协定条款,信达生物将获得3.5亿美元首付款,在达成后续特定里程碑事件后,还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外,信达生物有权就各产品在大中华区以外的净销售额获得梯度的销售分成。消息一出,资本市场反响热烈,信达生物股价一度大涨超...
Source Link春节前夕,医药圈上演了一场重磅大戏——信达生物和礼来这对“老搭档”,达成了第七次全球战略合作,将携手推进肿瘤及免疫领域创新药物的全球研发。根据协定条款,信达生物将获得3.5亿美元首付款,在达成后续特定里程碑事件后,还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外,信达生物有权就各产品在大中华区以外的净销售额获得梯度的销售分成。消息一出,资本市场反响热烈,信达生物股价一度大涨超...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.